Overview of D2000

Quick Facts: Dihydrotachysterol

Property	Description
Active Ingredient	Dihydrotachysterol (DHT)
Form	Oral tablet, capsule, or solution
Pharmacological Class	Vitamin D Analog (Antihypocalcemic Agent)
General Purpose	Regulates blood calcium and phosphate levels
Origin	Synthetic (derived from Vitamin D2)

D2000: A Synthetic Vitamin D Analog for Mineral Regulation

The medicine D2000 is a prescription-only preparation containing the single active ingredient Dihydrotachysterol (DHT), which is classified as a potent synthetic Vitamin D analog. Dihydrotachysterol functions as an antihypocalcemic agent, meaning its primary role is to counteract and prevent abnormally low concentrations of calcium in the blood. This compound is utilized for its effectiveness in mineral management.

Dihydrotachysterol is a secosteroid derived from the chemical modification of ergocalciferol, also known as Vitamin D2. Its synthetic origin is tied to a metabolic advantage that differentiates it from other Vitamin D forms: DHT is already in a form the body can immediately utilize for regulating minerals, bypassing a final activation step required in the kidneys. This characteristic allows for more direct and predictable control over the body’s calcium and phosphate metabolism.

Composition, Forms, and General Therapeutic Goal

D2000 is available for oral administration in several forms, including a tablet, a capsule, and a liquid oral solution or concentrate. As a single-ingredient product, it contains only Dihydrotachysterol alongside various carriers; the liquid and capsule forms often utilize an oil base due to the active ingredient's lipid-soluble nature. The availability of liquid forms is a key feature, often preferred for patients who may require highly tailored micro-doses.

The overarching therapeutic goal of D2000 is the maintenance of mineral balance by boosting the body's calcium levels. It achieves this by increasing the absorption of calcium from the intestines and promoting its mobilization from storage sites, ensuring the steady availability of this essential mineral. This functional capacity ensures that the nervous system and musculature have the calcium necessary for proper function, such as when regulating mineral levels in patients with chronic deficiencies.

Regulatory References

What side effects are possible with D2000?

Possible Side Effects and Safety Information

The official safety profile of D2000 (Dihydrotachysterol) is fundamentally structured around the risk of hypercalcemia, which is an abnormally high level of calcium in the blood and the primary adverse effect documented in regulatory labeling. The occurrence of adverse reactions is tied to the degree of overcorrection in mineral balance, rather than standard frequency categories (like Common or Rare).

Documented Adverse Reactions and Systemic Effects

Adverse reactions are primarily recognized as signs of developing toxicity and affect multiple system-organ classes, consistent with regulatory reporting. Early symptoms may include Gastrointestinal Disorders (anorexia, nausea, vomiting, dry mouth) and Musculoskeletal Disorders (bone pain, muscle weakness). Nervous System Disorders like headache and vertigo are also documented as early signs.

Progression of hypercalcemia can involve Renal and Urinary Disorders, characterized by increased thirst and urination (polyuria, polydipsia), and potentially lead to impaired kidney function. The effects of the medicine's activity and potential for toxicity may persist for up to one month after treatment is stopped.

Serious Adverse Reactions and Restrictions

Serious adverse reactions documented in official sources are consequences of severe, unchecked hypercalcemia and include Hypercalcemic Crisis and Metastatic Calcification, which is the deposition of calcium in soft tissues such as the heart and kidneys.

The medicine is formally contraindicated in patients with pre-existing hypercalcemia, hypervitaminosis D, and abnormal sensitivity to Vitamin D. For specific patient populations, the FDA classifies it as Pregnancy Category C, meaning its use is constrained, and caution is noted for use in lactation and in patients with a history of renal stones.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of D2000 (Dihydrotachysterol) leads to the documented manifestations of hypercalcemia, or excessive calcium in the blood. Early indications of overdosage may include weakness, headache, anorexia, vomiting, abdominal cramps, increased thirst (polydipsia), and increased urination (polyuria). As hypercalcemia progresses, the patient may exhibit more severe neurological signs such as ataxia, lethargy, disorientation, and syncope.

A severe overdose or prolonged toxicity can lead to life-threatening outcomes documented in regulatory labeling, including generalized soft-tissue calcification affecting vital organs like the heart, blood vessels, and kidneys. Other serious complications include cardiac arrhythmias, seizures, stupor, and coma, potentially resulting in renal or cardiovascular failure.

Immediate medical attention must be sought for any progressive or severe signs of overdose. For a hypercalcemic crisis, vigorous treatment is required. Official management procedures include the immediate discontinuation of D2000 and supplemental calcium, combined with hydration (liberal fluid intake or intravenous saline). Serum calcium levels must be measured until they return to the normal range. A specific regulatory caution notes that acute hypercalcemia may exacerbate the tendency toward cardiac arrhythmias in patients concurrently receiving digitalis drugs.

Therapeutic Uses of D2000

D2000: Main Uses and Therapeutic Benefits

D2000 (Dihydrotachysterol) is commonly used to help with conditions characterized by symptoms related to systemic imbalance of essential minerals. Its primary therapeutic areas include managing hypocalcemia associated with hypoparathyroidism and treating structural disorders like rickets and osteomalacia.

The medication is generally used for managing conditions presenting with recurrent or episodic manifestations of low calcium. It plays a role in addressing symptoms of increased neurological or muscular activity, such as painful cramping, twitching, and spasms (tetany). This supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable. The medication is generally applied in contexts where supportive symptom management is appropriate:

“It is commonly used to help with symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.”

D2000 is also considered relevant in contexts involving heightened systemic burden due to renal osteodystrophy and skeletal deficiencies. It contributes to improved day-to-day comfort during periods of symptoms related to physical discomfort and bone weakness. The key indications where this medication may be part of symptomatic management include hypoparathyroidism, rickets, osteomalacia, and hypocalcemia, including those conditions marked by heightened physiological stress.

Quick Fact: Focus on Neuromuscular Symptoms
Primary Symptom Focus	Muscle spasms, cramps, twitching, and tingling (paresthesia)
Primary Supportive Role	Assists with maintaining functional stability and easing distress during acute episodes.
Relevant Clinical Context	Chronic maintenance therapy and post-surgical mineral management.

Eligibility and Restrictions for Use

Who Can and Cannot Use D2000?

The population eligibility for D2000 (Dihydrotachysterol) is strictly defined by regulatory documents, emphasizing the risk of hypercalcemia (high blood calcium) due to the drug’s potent effect on mineral regulation.

Eligibility Scope

Category	Official Regulatory Statement (Status)
Populations for whom use is contraindicated	Patients with pre-existing Hypercalcemia or Hypervitaminosis D (Vitamin D toxicity) (Absolute Prohibition) [RxList, NIH].
Populations for whom use is allowed	Adults and Children are established populations for use in treating conditions like hypoparathyroidism and rickets [NIH].
Age-related eligibility rules	Pediatric Use is established but the narrow margin of safety mandates that dosing must be highly individualized [RxList]. Older Adults (65 and over) have insufficient data from clinical studies to determine if their response differs from younger patients [RxList].
Physiological Restrictions	Pregnancy is classified as Category C (Use is conditional only if the potential benefit justifies the potential risk to the fetus) [RxList]. Use in Nursing Mothers is not recommended without caution, as excretion into breast milk is not known [RxList].
Condition-specific eligibility rules	Use in patients with Renal Impairment or a history of Renal Stones must proceed with caution [Medscape, RxList]. Patients with Renal Osteodystrophy who have hyperphosphatemia must also use concurrent phosphate binders [DailyMed].

Eligibility Classifications

Category	Classification Details
Eligibility severity classification	Absolute Contraindication (Hypercalcemia); Category C (Pregnancy); Use with Caution (Renal Impairment, Nursing Mothers) [RxList].

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use D2000 primarily by establishing absolute prohibitions against use in patients who already have high mineral levels, specifically hypercalcemia. For other populations, such as pregnant patients or those with renal impairment, eligibility is defined as restricted or conditional, meaning the drug may only be used if specific, officially documented precautions and close monitoring are met. These rules ensure that eligibility is strictly governed by the potential risk of mineral imbalance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dihydrotachysterol (D2000) interactions are primarily governed by its effect on mineral balance and its metabolic pathways, as defined in regulatory documents. The official profile identifies combinations that lead to either additive toxicity or altered plasma exposure.

Documented Interaction Patterns

Interacting Substance/Class	Official Regulatory Outcome/Restriction
Other Vitamin D Analogs/Calcium Supplements	Restricted due to the increased risk of severe hypercalcemia (additive effect).
Thiazide Diuretics	Significantly increases the risk and severity of hypercalcemia (pharmacodynamic synergy).
Cardiac Glycosides (Digitalis)	Increases the risk of ventricular arrhythmias; caution required due to hypercalcemia potentiating cardiotoxicity.
Anticonvulsants (e.g., Phenytoin)	Decreased therapeutic efficacy of D2000 due to increased hepatic metabolism.
Bile Acid Sequestrants	Results in decreased serum concentration of D2000 via reduced intestinal absorption.
Corticosteroids	Decreased therapeutic efficacy due to pharmacodynamic antagonism of calcium regulation.
Grapefruit Juice	May officially alter the blood levels and effects of the medicine.

The regulatory documents establish that the official interaction profile centers on two critical areas: combinations that cause an increased systemic calcium load and combinations that affect the drug’s plasma exposure. Caution is specifically noted for interactions that may be more clinically significant in populations, such as the increased risk with Thiazide Diuretics in patients with compromised renal function.

Mechanism of Action

D2000 functions as a competitive antagonist that selectively targets the sphingosine-1-phosphate receptor 1 ( S1P1) subtype, primarily located on the surface of circulating T and B lymphocytes. The molecule binds to the receptor, thereby preventing the natural ligand, sphingosine-1-phosphate (S1P), from initiating its signaling cascade. This binding induces the functional antagonism of the receptor.

Following antagonism, D2000 promotes the rapid and temporary internalization and sequestration of the S1P1 receptors from the cell surface into the cytoplasm. Since S1P1 surface activity is necessary for lymphocytes to receive the migratory signal to exit secondary lymphoid organs—such as the lymph nodes and thymus—this reduction in surface S1P1 interrupts the cells' egress signals.

The resulting physiological consequence is the transient and reversible sequestration of lymphocytes within these lymphoid tissues. This mechanism mediates a dose-dependent reduction in the absolute count of circulating T and B lymphocytes in the peripheral blood, thereby modulating the systemic immune cell distribution.

Dosage and Administration Information

How to Use D2000 (Dihydrotachysterol)

D2000 is administered strictly via the oral route and is available as a tablet, capsule, or a liquid oral solution (0.2 mg/mL). The liquid solution requires measurement using a calibrated dropper to ensure the precise amount is taken. The medicine is taken once daily and may be administered with or without food.

Official Dosing and Administration Protocol

The dosage regimen for D2000 is structured into two phases: an initial loading period and a long-term maintenance period, with the dosage being highly individualized for each patient.

Usage Phase	Adult Dosing Range	Key Frequency Pattern
Initial (Loading)	0.8 mg to 2.4 mg	Daily for approximately 4 days
Maintenance	0.2 mg to 1 mg	Once Daily (Long-term)

Pediatric regimens are specifically outlined for use in children and neonates, requiring careful attention to the prescribed mg and mcg amounts.

Procedural Conditions for Use

Proper use of D2000 mandates specific procedural constraints. Administration requires concomitant adequate intake of calcium, often through the use of supplemental products. Furthermore, to manage therapy and prevent dose-related complications, the dosage adjustment process requires frequent monitoring of serum calcium levels. Adjustments to the maintenance dose are typically made at 4- to 8-week intervals to account for the drug's slow action, and the dose must be withheld immediately if calcium levels exceed the therapeutic range.

Recent Clinical Evidence

Research evidence / Overview of studies for D2000

This overview describes the scope of clinical research conducted for Dihydrotachysterol (D2000), focusing only on the types of studies, the populations examined, and what findings were reported in authoritative sources. It does not provide medical advice or state expected personal outcomes.

Evidence for Use in Managing Hypocalcemia Related to Hypoparathyroidism

The research concerning D2000 for managing low calcium levels (hypocalcemia) linked to hypoparathyroidism includes both randomized controlled trials (RCTs) and long-term observational studies. These studies have primarily explored how the medicine was studied for the regulation of calcium levels in patients who have undergone surgery affecting the parathyroid glands or who have chronic forms of the condition.

Researchers monitored patients for outcomes related to serum calcium level normalization and also examined secondary biomarkers like serum phosphate concentrations. Outcomes related to systemic or functional imbalance were tracked, such as outcomes related to physical discomfort like muscle spasms and twitching. Studies comparing D2000 with other Vitamin D-related medicines reported measured patterns of mineral concentrations in the observed patient groups.

What remains uncertain is that the body of comparative evidence is primarily against other older forms of Vitamin D, and comparative evidence is lacking for direct comparison to newer replacement therapies.

Research on Mineral Regulation for Bone Disorders (Rickets and Osteomalacia)

Studies examined D2000 in conditions involving periods of heightened symptoms, specifically rickets in children and osteomalacia in adults. Evidence in this area comes from clinical trials and established scientific reports that focused on outcomes related to physical discomfort and deficient bone mineralization.

For rickets, studies included pediatric populations and tracked changes in radiographic features of the bones, such as mineralization at the growth plates, and monitored children's height Z-scores. For osteomalacia, research described measured changes in bone mineralization markers and documented how symptoms evolved in the observed adult populations. Findings from these studies reported measured concentrations of calcium and phosphate in the observed patient groups.

Studies in Patients with Chronic Kidney Impairment and Mineral Imbalances

Research involving D2000 has also been evaluated in patients with chronic renal insufficiency (impaired kidney function). These studies, which included randomized comparative trials and observational cohorts, aimed to understand mineral regulation in a scenario where the kidney's ability to process minerals is reduced.

The studies monitored serum calcium and phosphate control and tracked the concentration of parathyroid hormone (PTH) in the blood. Studies showed patterns related to mineral stabilization in the studied patient groups.

Understanding Research Gaps and Limitations

The evidence base for D2000, while substantial due to its long history of use, has certain acknowledged limitations that scientific bodies have noted. Many of the key comparative studies were conducted during earlier periods, meaning there is limited comparative evidence directly against the very latest classes of non-Vitamin D replacement therapies. The follow-up durations were limited in some key efficacy trials, and evidence quality varies across studies. Overall, the research highlights what is known about group patterns but emphasizes that research does not determine whether an individual will respond similarly.

Key Studies & References

Editorial: Rickets and osteomalacia, from genes to nutrition

Frequently Asked Questions (FAQ)

Common questions about D2000 (FAQ)

Q: How quickly do people generally notice the effects of D2000?

Official sources note that measured changes in blood calcium levels may be observed within a few days of initiating therapy. Authoritative medical sources describe D2000 as a form of Vitamin D with a relatively quick onset of action.

Q: Is D2000 a drug that needs to be taken long-term?

Official regulatory documents outlining the dosage for conditions like hypoparathyroidism include a defined initial period followed by a long-term maintenance phase. This suggests the medicine’s use is typically intended for the chronic management of the underlying condition.

Q: Does D2000 cause weight gain or weight loss?

The official safety information for D2000 lists anorexia, which is a loss of appetite, as an early symptom of developing hypercalcemia. Official safety documentation does not routinely list generalized weight gain as a common adverse effect.

Q: Is it typical to feel a bit nauseous when first starting D2000?

According to the official product information, nausea and vomiting are explicitly documented as early symptoms of developing hypercalcemia (high blood calcium). These symptoms are recognized as signals of potential overcorrection of mineral balance, which is the drug's primary adverse effect.

Q: Is it safe to take D2000 if I already take a vitamin supplement?

Official guidance restricts the use of D2000 alongside other products containing Vitamin D Analogs or Calcium Supplements. Official guidance indicates that combining these products may significantly increase the risk of severe hypercalcemia (dangerously high blood calcium).

Q: What is the difference between D2000 and the generic version of the medicine?

D2000 is a prescription medicine containing the single active ingredient, Dihydrotachysterol (DHT). The term 'generic version' refers to any medicine that contains this same active ingredient, DHT, without the specific brand name D2000.

Q: How long does the effect of one dose of D2000 typically last?

Technical drug information describes D2000 as having a shorter half-life compared to non-activated Vitamin D. However, its biological effects and potential for toxicity are formally documented to persist for up to one month following the end of treatment.

Q: Can D2000 be safely stopped suddenly, according to official advice?

Official regulatory guidance instructs that the dose must be withheld immediately if blood calcium levels exceed the therapeutic range. This is done to reverse potential toxicity, but official guidance does not provide instructions for the abrupt cessation of therapy unrelated to toxicity.

Q: Are allergic reactions common with D2000?

The official safety profile is primarily structured around the risk of hypercalcemia and the associated symptoms of mineral imbalance. Allergic reactions are not listed among the primary or early documented adverse reactions in most official patient-facing materials.

Q: How long does D2000 stay in the body after the last dose?

The drug's technical characteristics include a relatively shorter half-life than non-activated Vitamin D. Its biological effects and the potential for toxicity are formally documented to persist for up to one month following the end of treatment.

Q: Can D2000 affect my ability to drive or operate machinery?

Official safety information lists headache and vertigo (dizziness) as possible early symptoms of hypercalcemia. Patients are generally advised to be aware of such effects, as they could affect concentration or motor skills required for driving or operating machinery.

Q: Is it true that D2000 is only for severe cases of the condition?

D2000 is officially indicated for conditions such as hypoparathyroidism, rickets, and osteomalacia. Official indications define the use based on the presence of the underlying medical condition, not on the disease's overall severity.

Q: What is the half-life of D2000 as described in technical documents?

Technical drug information describes D2000 as having a relatively short half-life compared to other non-activated Vitamin D forms. This characteristic is noted in some documents as a feature that can help manage the hypercalcemia effects.

Q: Does D2000 affect mood or sleep patterns?

Official safety information lists symptoms of toxicity that relate to the central nervous system, such as headache and vertigo. Specific claims about general mood changes or sleep disturbances are not uniformly documented in the primary regulatory adverse effect profiles.

Q: Is it required to have a specific test before starting D2000?

The medicine is strictly contraindicated (prohibited) for patients with pre-existing hypercalcemia (high blood calcium). Official prescribing guidance is grounded in the absolute contraindication against use in patients with pre-existing high blood calcium.

Q: Are there any specific lifestyle changes that official sources suggest when using D2000?

Proper administration of D2000 mandates specific procedural constraints. Official administration documents note the necessity of concomitant adequate intake of calcium, which often involves the use of supplemental products.

Q: What information is available about D2000 use in children?

Official prescribing information confirms D2000 is an established treatment for rickets and hypoparathyroidism in the pediatric population. Specific dosage is outlined for use in neonates and children, though strict individualization is required due to the drug’s narrow safety margin.

Q: How is D2000 different from a vitamin or supplement?

D2000 is a potent synthetic Vitamin D analog that is classified as a prescription-only drug. It is chemically modified to bypass a major activation step in the body, providing a more direct and predictable effect on mineral regulation than standard over-the-counter Vitamin D supplements.

How should D2000 be stored and disposed of?

How to Store and Dispose of D2000 (Dihydrotachysterol)

The storage and disposal of D2000 must comply strictly with official regulatory labeling to maintain the product's integrity.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C.
Protection	Must be protected from light and stored away from moisture. Do not freeze.
Container	Keep in the original container and ensure it is tightly closed.
Child Safety	Keep the medicine out of the reach and sight of children.

Stability and Disposal

Liquid forms must be discarded four months after first opening the bottle. Unused or expired D2000 must not be discharged into sewer systems. Disposal must be conducted in accordance with applicable laws and regulations for pharmaceutical waste.

D2000